C
06185
CanSino Biologics
23.340
-0.840-3.47%Closed16:08 08/19 HKT
OPEN/PREV CLOSE26.840/23.340
TODAY RANGE26.840-40.000
VOL40.64M
MARKET CAP7.92B
52 WEEK RANGE19.220-56.550
AVG VOL (3M)1.42M
% TURNOVER16.45%
TURNOVER1.39B
P/E (TTM)-6,969.565
% RANGE56.38%
EPS(TTM)-0.005
P/E(FORWARD)54.293
P/B1.420
BVPS22.583
DIVIDEND--
P/S6.286
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.25B
SHARES OUTSTANDING247.04M
NEXT EARNINGS08/20-08/24
FREE FLOAT132.67M
LOT SIZE200
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·04/30 10:22
CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives
Simply Wall St·12/29/2025 22:54
CanSino Biologics Inc.'s (HKG:6185) last week's 4.5% decline must have disappointed individual investors who have a significant stake
Simply Wall St·11/20/2025 01:15
Benign Growth For CanSino Biologics Inc. (HKG:6185) Underpins Its Share Price
Simply Wall St·10/29/2025 22:23
CanSino Biologics Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Simply Wall St·10/28/2025 14:20
CanSino Biologics (SEHK:6185) Losses Worsen, Undervalued Against DCF Despite 120% Earnings Growth Forecast
Simply Wall St·09/29/2025 07:11
CanSino Biologics Inc.'s (HKG:6185) stock price dropped 9.0% last week; individual investors would not be happy
Simply Wall St·09/11/2025 18:42
CanSino Biologics (SEHK:6185) Reports Rising Sales And Revenue
Simply Wall St·09/04/2025 22:11
Asian Market Insights: 3 Companies Priced Below Estimated Value
Simply Wall St·08/24/2025 01:03
CanSino Biologics Inc. (HKG:6185) Just Reported And Analysts Have Been Lifting Their Price Targets
Simply Wall St·08/22/2025 23:26
CanSino Biologics Second Quarter 2025 Earnings: CN¥0.006 loss per share (vs CN¥0.22 loss in 2Q 2024)
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.